Advancing the next generation of precision oncology and inflammation therapeutics.
At Allterum Therapeutics, we are pioneering breakthrough medicines shaped by rigorous science, deep clinical insight, and an unwavering commitment to the patients who motivate everything we do.
We advance precision medicine through uncompromising science and meaningful innovation—developing oncology and inflammation therapies that deliver extraordinary accuracy, transform treatment pathways, and change patient lives… because #PatientsCantWait
Learn MoreAllterum Therapeutics, Inc. is a biopharmaceutical company developing multiple precision oncology and inflammation therapeutics. Our lead clinical development therapeutic targets the IL-7 pathway for the treatment of CD127 expressing hematologic malignancies, major solid tumors, and autoimmune disorders.
Our Partnerships & Collaborators
“ I am excited to work with Allterum to develop a much-needed option for the treatment of children with T-cell ALL.”
-Eric Schafer, M.D., M.H.S. Assist. Professor, Pediatrics-Oncology | Texas Children's Hospital & Baylor College of Medicine
“ ”After years of searching for a way to help those kids who have no effective treatment for their leukemia, I’m thrilled to see Allterum take our antibody into the clinic.”
-Scott Durum, Ph.D. Section Chief and Antibody discoverer | Cytokine and Immunity Section | National Cancer Institute